8. Human Systems, a pharmaceutical company, is expected to experience a high rate of earnings and dividend growth in the next 5 years as a result of having developed a cold remedy that reduces the effects of the common cold to an average of 1-2 days. You, a stock analyst, must determine if Human Systems' stock is underpriced/overpriced based on your firm's projection of the company's rate of growth over the next several years. The information below will help you to make that determination: Human Systems' stock is currently trading at a stock price of $92.75. Human Systems' expected growth rate in earnings and dividends during the nonconstant growth period is 20% for years 1 to 3 and 10% in years 4 and 5. The rate of normal, constant growth after the nonconstant period is 5%. The last dividend Human Systems paid was $2.00. The beta value for Human Systems' stock is 1.21. First, use CAPM to determine the shareholder's required rate of return for an investment in Human Systems based on the stock's beta